Carmine De Angelis: Trop-2 Expression Limits in Breast Cancer ADCs
Carmine De Angelis, Associate Professor at Southern Higher School, Naples, shared on LinkedIn: “As ADCs continue to transform the treatment landscape of metastatic breast cancer, understanding who…
Read the full articleYou might also wanna read
ADCs Continue to Make First-Line Inroads in Triple-Negative Breast Cancer
(MedPage Today) -- Antibody-drug conjugates (ADCs) are becoming an increasingly relevant first-line treatment option for metastatic triple-n
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd
Conditions : Advanced Breast Cancer; Metastatic Breast Cancer; HER2 Positive; HR Positive Interventions : Drug: Trastuzumab deruxtecan; Drug
De-Escalation, Genomics and Multidisciplinary Care Redefines Breast Cancer Treatment
Amanda Amin, MD, Janice Lyons, MD and Alberto Montero, MD, explore the evolution of breast cancer treatment. The discussion highlights how p
Research on AI Models for Predicting Breast Cancer Treatment Effectiveness to Guide Her-2 Targeted ADC Therapy
Conditions : Breast Cancer Sponsors : Zhejiang Cancer Hospital Not yet recruiting
Performance of Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer
Conditions : Breast Cancer (Triple Negative Breast Cancer (TNBC)) Interventions : Other: Non interventional study Sponsors : Assistance Publ
Comments
Sign in to join the conversation.
No comments yet. Be the first.